ABECMA (idecabtagene vicleucel) | FDA
2024年12月6日 · ABECMA is the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapies including an immunomodulatory agent, a proteasome...
FDA Approves First Cell-Based Gene Therapy for Adult Patients …
The U.S. Food and Drug Administration approved Abecma (idecabtagene vicleucel), a cell-based gene therapy to treat adult patients with multiple myeloma who have not responded to, or whose...
U.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma …
2024年4月5日 · Abecma is now approved in the U.S., Japan, Switzerland and the EU for earlier use for triple-class exposed relapsed and/or refractory multiple myeloma, underscoring BMS’ commitment to delivering Abecma globally, with consistently high manufacturing success rates and continuous increases in capacity
CAR T Cell Therapy for Relapsed/Refractory Multiple Myeloma - ABECMA …
Discover ABECMA® (idecabtagene vicleucel), the first CAR T cell therapy for relapsed/refractory multiple myeloma, how it works, how it helps, and see patient stories. See Safety Info and Boxed WARNINGS.
Abecma - European Medicines Agency (EMA)
Abecma is a medicine used to treat adults with multiple myeloma (a cancer of the bone marrow) when the cancer has come back (relapsed) and has not responded to treatment (refractory). It is used in adults who have received at least two prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti‑CD38 antibody and ...
Idecabtagene vicleucel - Wikipedia
Idecabtagene vicleucel, sold under the brand name Abecma, is a cell-based gene therapy to treat multiple myeloma. [3] [7] [8] The most common side effects include cytokine release syndrome (CRS), infections, fatigue, musculoskeletal pain, and a weakened immune system (hypogammaglobulinemia). [4] [7]
FDA approves idecabtagene vicleucel for multiple myeloma
On March 26, 2021, the Food and Drug Administration approved idecabtagene vicleucel (Abecma, Bristol Myers Squibb) for the treatment of adult patients with relapsed or refractory multiple myeloma...
Mechanism of Action | ABECMA® (idecabtagene vicleucel)
2019年5月11日 · Explore the mechanism of action for ABECMA® (idecabtagene vicleucel). See Safety Info and Boxed Warnings.
CAR T Cell Therapy for R/R Multiple Myeloma | ABECMA® …
ABECMA® is a CAR T cell therapy for adult patients with Relapsed/Refractory Multiple Myeloma (RRMM). See Safety Info and Boxed WARNINGS..
Bristol Myers Squibb - Bristol Myers Squibb’s Abecma …
2024年3月20日 · Abecma is the first chimeric antigen receptor (CAR) T cell immunotherapy approved in the European Union (EU) for use in earlier lines of therapy for relapsed and refractory multiple myeloma. This expanded approval of Abecma covers all EU member states.* In the EU, Abecma has maintained its Orphan Designation for the treatment of multiple myeloma.